Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment

Erlotinib (Tarceva ® ) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasi...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology and therapy 2022-05, Vol.12 (5), p.1281-1286
Main Authors: Kim, En Hyung, Kim, Dong Min, Lee, Ji Yeoun
Format: Article
Language:English
Subjects:
Care and treatment
Case Report
Dermatology
Diagnosis
Dosage and administration
Drug therapy
Erlotinib
Health aspects
Internal Medicine
Lung cancer, Non-small cell
Medicine
Medicine & Public Health
Neovascularization
Oral and Maxillofacial Surgery
Plastic Surgery
Quality of Life Research
Xanthoma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Erlotinib (Tarceva ® ) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasias, and abnormal eyelash growth. A 56-year-old man and a 46-year-old man visited the dermatology clinic complaining of yellowish papuloplaques and acneiform eruption on the face. They had been treated with erlotinib for lung cancer. Since patients using EGFR inhibitors are increasing, physicians should be aware that xanthomatous change can occur in severe acneiform eruptions after erlotinib treatment.
ISSN:2193-8210
2190-9172
DOI:10.1007/s13555-022-00739-5